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SENCAR Mouse Skin Tumorigenesis Model
Versus Other Strains and Stocks of Mice
by Thomas J. Slaga*
The SENCAR mouse stock was selectively bred for eight generations for sensitivity to skin tumor
induction by the two-stage tumorigenesis protocol using 7,12-dimethylbenz(a)anthracene (DMBA) as the
initiator and 12-0-tetradecanoylphorbol-13-acetate (TPA) as the promoter. The SENCAR mouse was de-
rived by crossing Charles River CD-1 mice with skin-tumor-sensitive mice (STS). The SENCAR mice are
much more sensitive to both DMBA tumor initiation and TPA tumor promotion than CD-1, BALB/c, and
DBA/2 mice. An even greater difference in the sensitivity to two-stage skin tumorigenesis is apparent
between SENCAR and C57BL/6 mice when using DMBA-TPA treatment. However, the SENCAR and
C57BL/6 mice have a similar tumor response to DMBA-benzoyl peroxide treatment, suggesting that TPA
is not an effective promoter in C57BL/6 mice. The DBA/2 mice respond in a similar manner to the SENCAR
mice when using N-methyl-N-nitro-N-nitrosoguanidine (MNNG)-TPA treatment. The SENCAR mouse
model provides a good dose-response relationship for many carcinogens used as tumor initiators and for
many compounds used as tumor promoter. When compared to other stocks and strains of mice, the
SENCAR mouse has one of the largest data bases for carcinogens and promoters.
Introduction
It is well known that skin tumors (papillomas, kera-
toacanthomas, and squamous cell carcinomas) can be
induced in mice by a complete carcinogenesis protocol
(carcinogen given repetitively) or by the sequential ap-
plication of a subthreshold dose of a carcinogen (initi-
ation stage) followed by repetitive treatment with a
weak or noncarcinogenic tumor promoter (promotion
stage). The initiation stage requires only a single ap-
plication of either a direct or an indirect carcinogen at
a subthreshold dose and is essentially irreversible,
whereas the promotion stage is brought about by re-
petitive treatments after initiation and is reversible for
a period of time but later becomes irreversible (1,2).
To provide a better understanding of the SENCAR
mouse and its relative sensitivity to skin carcinogenesis
when compared to other stocks and strains ofmice, this
paper first discusses the derivation of the SENCAR
mouse.
Derivation
The SENCAR stock ofmice was selectively bred for
sensitivity to skin tumor induction by two-stage tu-
morigenesis. Consequently, the SENCAR mouse is ex-
tremely sensitive to two-stage carcinogenesis and co-
incidentally sensitive to complete carcinogenesis. The
SENCAR mouse was derived from crossing Charles
River CD-1 mice with skin tumor-sensitive mice (STS)
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and selected for sensitivity to 7,12-dimethylbenz-
(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-
13-acetate (TPA) two-stage carcinogenesis for eight
generations starting with the F1 cross as originally de-
scribed by Boutwell (2). Figure 1 outlines the method
used by Boutwell to select for the STS mice. A similar
selection procedure was used by Boutwell and cowork-
ers to derive the SENCAR mice as outlined in Figure
2. In both cases, the mice developing the earliest and
most numerous papillomas after initiation-promotion
treatment were selected for each breeding.
Comparison of SENCAR Mice to Other
Stocks and Strains of Mice
SENCAR mice are between 10 and 20 times more
sensitive to DMBA tumor initiation than CD-1 mice
(Table 1). However, as shown in Table 2, they are only
between three and five times more sensitive to
benzo(a)pyrene (B[a]P) tumor initiation than CD-1 mice
(3). In addition, SENCAR mice are two to three times
more sensitive to TPA promotion than CD-1 mice (3).
BALB/c mice also appear to be consistently less sen-
sitive to two-stage tumorigenesis than SENCAR mice
(4).
Although several stocks and strainsofmice havebeen
used in skin tumor induction experiments very little
dose-response data are available. In addition, with the
exception of studies on SENCAR and C57BL/6 mice,
very few comparative studies have been performed to
determine the relative sensitivity ofvarious stocks and
strains of mice to carcinogens. An even greater differ-T. J. SLAGA
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Table 1. Comparison of the tumor-initiating activity of DMBA
in SENCAR vs. CD-1 mice.a
No. of No. of No. of % of
DMBA papillomas mice with papillomas mice with
dose, per mouse papillomas per mouse papillomas
Mice nmole at 15 wk at 15 wk at 25 wk at 25 wk
SENCAR 100 22.0 100 24.0 100
SENCAR 10 6.4 100 7.0 100
SENCAR 1 3.2 90 3.8 95
SENCAR 0.1 0.3 15 0.6 20
SENCAR o.Ob 0 0 0.1 10
CD-1 100 4.8 75 5.6 90
CD-1 10 2.2 60 3.0 72
CD-1 1 0 0 0.2 10
CD-1 0.1 0 0 0 0
CD-1 0.OC 0 0 0.2 10
aData taken from Slaga and Fischer (33). Eachexperimental group
is an average ofthreeexperiments containing30miceperexperiment.
DMBA was applied topically once and followed 7 days later by twice
weekly promoting applications of 8.5 nmole of TPA. The maximum
percent standard deviation for all groups was 15%.
bTPA-only group; the mice received twice weekly applications of
8.5 nmole of TPA for 25 wk.
ence in the sensitivity to two-stage skin carcinogenesis
is apparent between SENCAR and C57BL/6 mice than
between the SENCAR and CD-1 mice. C57BL/6 mice
are very refractory to two-stage skin carcinogenesis by
B(a)P-TPA. As shown in Table 3, even high initiating
doses of B(a)P (1600 nmole) and high promoting doses
of TPA (10 ,ug) are quite ineffective in causing skin
tumors in C57BL/6 mice. However, C57BL/6 mice do
respond to complete carcinogenesis by B(a)P and, in
this regard, they appear to be equal to or slightly more
sensitive than SENCAR mice (5). This unequal suscep-
tibility to complete and two-stage carcinogenesis within
a stock or strain of mice strongly suggests that the
promotional phases of complete and two-stage carcin-
ogenesis are dissimilar. In addition, differences in sen-
sitivity to initiation and promotion among mice may be
caused by alterations in the promotional phase of two-
stage carcinogenesis. In this regard, we have recently
found that benzoyl peroxide is an effective promoter in
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Table 2. Comparison of the tumor-initiating activity of B(a)P in
SENCAR vs. CD-1 mice.a
No. of No. of No. of % of
DMBA papillomas mice with papillomas mice with
dose, per mouse papillomas per mouse papillomas
Mice nmole at 15 wk at 15 wk at 25 wk at 25 wk
SENCAR 200 7.6 100 8.2 100
SENCAR 100 3.4 78 3.8 80
SENCAR 50 1.4 56 1.6 60
SENCAR 10 0.6 36 0.9 42
SENCAR ob 0 0 0.1 10
CD-1 200 1.4 56 3.8 72
CD-1 100 1.0 44 1.8 58
CD-1 50 0.5 36 0.7 40
CD-1 10 0 0 0.1 10
CD-1 oc 0 0 0.1 10
aData taken from Slaga and Fischer (33). The maximum percent
standard deviation for all groups was 18%.
-bTPA-only groups; the mice received twice weekly applications of
8.5 nmole of TPA for 25 wk.
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Table 3. Initiation-promotion in SENCAR and C57BL/6 mice.a
Result
SENCAR C57BL/6
Treatment mouse mouse
Repetitive applications Low level of No tumors
of TPA for 52 weeks papillomas (5-20%) and
without initiation carcinomas (<15%)
No dose-response
relationship
Repetitive applications Less than 5% tumors No tumors
of benzoyl peroxide for
52 weeks without
initiation
Repetitive application Dose-response Low level of
of various levels of relationship in papillomas
TPA peroxide after papillomas (early) and (<5%) and
initiation with 50-1600 carcinomas (late) carcinomas
nmole B(a)P (<10%)
Repetitive applications Dose-response 45% carcinoma
of various levels of relationship in incidence
benzoyl peroxide after papillomas (early) and
initiation carcinomas (late)
aData of Reiners et al. (5).
C57BL/6 and SENCAR mice (5). For some reason, TPA
is not an effective promoter in C57BL/6 mice.
Recently, DiGiovanni and coworkers (6) have found
that the DBA/2 mice are much less sensitive to DMBA-
TPA two-stage tumorigenesis than the SENCAR mice.
Ifhigh initiating doses (400 nmole/mouse) ofDMBA are
used on the DBA/2 mice followed by TPA promotion,
they do respond with a high tumor yield. When DBA/
2 mice are compared with SENCAR mice following ini-
tiation with N-methyl-N-nitro-N-nitrosoguanidine
(MNNG) and TPApromotion, the DBA/2 and SENCAR
mice respond with a nearly identical tumor response
(6).
Carcinogens and/or Initiators Used With
the SENCAR Mouse Model
The SENCAR mouse model currently has one ofthe
largest data bases for carcinogens and/or initiators. All
the carcinogens and/or initiators that have been tested
in both the CD-1 and SENCAR mice have been found
to be positive in both stocks ofmice. The major differ-
enceisrelated totheincreased sensitivity toandshorter
latent period for tumor development in the SENCAR
mice. As was the case in CD-1 mice, DMBA and B(a)P
show a good dose-response relationship in SENCAR
mice (Table 4). As can be seen, a good correlation exists
between the number of papillomas per mouse at 15
weeks and the final carcinoma incidence at 50 weeks.
The percentage ofmice with papillomas also has a rea-
sonable correlation, but the dose response relationship
is very narrow (Table 4).
The carcinogenicity of many polycyclic aromatic hy-
drocarbons (PAHs), metabolites, and derivatives has
been determined in the SENCAR mouse skin tumori-
Table 4. Dose-response studies on the ability of DMBA and
B(a)P to initiate skin tumors in SENCAR mice.'
No. of % of % of
papillomas mice with mice with
per mouse papillomas carcinomas
Initiator Dose, nmole at 15 wk at 15 wk at 50 wk
DMBA 100 22.0 100 100
DMBA 10 6.8 100 40
DMBA 1 3.2 93 22
DMBA 0.1 0.5 20 5
B(a)P 200 7.5 100 55
B(a)P 100 3.2 78 30
B(a)P 50 1.4 60 18
aData taken from Slaga and Fischer (33). The mice were treated
one week after initiation with twice weekly applications of 5 ,ug of
TPA.
genesis model (4,7-27). Besides the PAHs, a number
ofotherclassesofchemicalcarcinogenshavebeenfound
to be positive in a dose-response relationship as skin
carcinogens and/or initiators in the SENCAR mouse.
These classes include sterig-matocystin, urethane, 1,3-
propanesultone, 4-nitroquinoline-N-oxide, MNNG, N-
nitrosoethylurea (ENU), N-nitrosomethylurea, epi-
chlorohydrin, and ,-naphthylamine (Slaga et al., un-
published data). In this regard, both MNNG and ENU
have been found to be very potent skin carcinogens and
tumor initiators, which suggests that these compounds
will be useful, direct-acting carcinogens in the skin
model (Slaga and Nesnow, unpublished data). Several
other chemicals (dimethylnitrosamine, dimethylhydra-
zine, acetylaminofluorine, and 4-aminobiphenyl), which
have been found to be positive as carcinogens in certain
tissues, have been extensively studied in SENCAR
mouse skin and found to be negative as carcinogens
(Slaga et al., unpublished data). A possible explanation
may be the lack of metabolic activation of these com-
pounds inthe skin. In addition, severalcompounds such
as chloroform and malonaldehyde were also found to be
negative as carcinogens in the SENCAR mouse skin
tumorigenesismodel(Slagaandcoworkers, unpublished
data).
Anumberofenvironmentallyimportantcomplexmix-
tures have also been extensively studied for skin-car-
cinogenic and/or tumor-initiating activity in the SEN-
CAR mouse (28-32). Of the complex mixtures tested,
coke oven main and roofing tar both had strong skin
carcinogenic and tumor-initiating activity, whereas the
Nissan diesel exhaust sample was only a strong tumor
initiator.
Promoters Used With the SENCAR Mouse
Model
As in the case with carcinogens and/or tumor initia-
tors, not all the various skin tumor promoters tested
havebeenassayed in SENCAR mice. AsshowninTable
5, agood dose-response relationship exists forTPA skin
tumor promotion after DMBA initiation when consid-
ering either the number of papillomas per mouse at 15
weeks or the percentage of mice with squamous cell
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Table 5. Dose-response studies on the ability of TPA to promote
tumors after DMBA initiation.a
Time to No. of
first papillomas % with % with
TPA papilloma, per mouse papillomas carcinomas
Promoter dose, p.g wk at 15 wk at 15 wk at 50 wk
TPA 10 8 3.0 100 32
TPA 5 6 7.2 100 46
TPA 2 7 6.5 100 45
TPA 1 8 3.6 80 25
TPA 0.1 11 0.4 5 8
aSee Slaga and Fischer (33) for details. The mice were initiated
with 10 nmole of DMBA and promoted one week later with various
dose levels of TPA.
carcinomas at 50 weeks. The repetitive application of
the promoter TPA without initiation by DMBA in gen-
eral gives rise to a few tumors, but a dose-response
relationship has never been noted (Table 6). The max-
imum response observed after 50 weeks of treatment
with TPA was a 22% incidence ofmice with papillomas
and 5% with carcinomas.
Although the initiation stage appears to be irrever-
sible, the promotion stage is reversible, requiring a cer-
tainfrequency ofpromoterapplication toinduce tumors.
Table 7 compares the promoting activity of various
doses ofTPA when given either three times, two times,
or one time per week. In general, as the frequency of
TPA application decreases, the promoting activity also
decreases. It should be pointed out, however, that one
application per week of TPA after initiation by 20
nmoles of DMBA is still fairly effective in tumor pro-
motion. In constrast, high doses of TPA given once
every 2 weeks or once every 3 weeks are ineffective in
tumor promotion (33).
Besides TPA, several other phorbol ester tumor pro-
moters have been assayed in SENCAR mice. Phorbol
12,13-dibutyrate and 12-deoxyphorbol-13-decanoate
both show a good dose-response relationship (Slaga et
al., unpublished data). Although 4-O-methyl-TPA is
generally not considered a tumorpromoter, it does have
some promoting activity at doses greater than 200 [.g
per application. 12-O-Retinylphorbol-13-acetate was
also found to have skin tumor promoting activity but
less than that ofTPA. In general, mezerein can be con-
sidered a weak skin tumor promoter in SENCAR mice
(33,34).
Table 6. Dose-response studies on the ability of TPA to act as a
complete carcinogen in SENCAR mice.a
No. of % of mice with % of mice with
TPA dose, papillomas per papillomas at carcinomas at
,ug mouse at 50 wk 50 wk 50 wk
0 0 0 0
1 0.09 8 0
2 0.07 7 0
4 0.20 22 5
6 0.15 12 0
aThe mice (80 per group) were treated twice weekly with various
dose levels of TPA.
Table 7. Comparison of the frequency of application and dose of
TPA on skin tumor promotion.'
Frequency of No. of % of mice
DMBA application, papillomas with
initiation, TPA times per per mouse papillomas
dose, nmole dose, ,ug week at 16 wk at 16 wk
10 1 3 7.8 100
10 1 2 3.6 80
10 2 2 6.5 100
10 5 2 10.2 100
10 10 2 4.6 100
10 0.5 1 1.0 40
10 1 1 1.8 66
10 2 1 3.2 74
10 3 1 4.3 78
10 4 1 5.1 82
10 5 1 6.4 86
20 1 1 4.2 76
20 2 1 6.0 96
20 4 1 9.0 100
aThirty female SENCAR mice were used for each group. Data of
Slaga et al. (unpublished results).
A number ofother chemicals have been found to pro-
mote skin tumors in SENCAR mice. These chemicals
include telecidin, retinoic acid, benzoyl peroxide, lauryl
peroxide, cumene peroxide, decanoyl peroxide, cumene
hydroperoxide, tert-butyl hydroxperoxide, butylated
hydroxytoluene hydroperoxide, 1-fluoro-2,4-dinitroben-
zene, benzo(e)pyrene, anthralin, and chrysarobin
(1,33,35 and Slaga et al., unpublished data). A number
of chemicals have been found to be negative or very
weak as skintumorpromoters in SENCAR mice. These
chemicals include hydrogen peroxide, hydroquinone,
butylated hydroxyanisole, butylated hydroxytoluene,
calcium ionophore A23187, chloroquine, ouabain, chlor-
promazine, epichlorohydrin, chloroform, malonalde-
hyde, phenanthrene, 2-aminoanthracene, 1-aminoan-
thracene, phenanthrenequinone, and 2,3,7,8-
tetrachlorodibenzo-p-dioxin (Slaga et al., unpublished
data).
In terms of complex mixtures, diesel fuel was found
to have a moderate skin-tumor-promoting activity, but
was found to be negative as a carcinogen in SENCAR
mice (Slaga et al., unpublished data).
Conclusion
The SENCAR mouse is, in general, one of the most
sensitive stocks and strains of mice currently available
forboth complete and two-stage carcinogenesis studies.
The SENCAR mouse skin tumorigenesis model has one
of the largest data bases for skin carcinogens, tumor
initiators, tumor promoters, and anticarcinogens (an-
tiinitiators and antipromoters). The model provides ex-
cellent data on dose-response relationships when both
pure substances and complex mixtures are tested. The
two-stage tumorigenesis protocol can be considered a
reliable and relatively short-term bioassay for carcin-
ogens and promoters. This model has also been very
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important in determining the mechanism of action of
carcinogens, promoters, and anticarcinogens.
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